- Another active medical condition(s) or organ disease(s) that may either compromise
patient safety or interfere with the safety and/or outcome evaluation of the study
drug. While this exclusion is not limited to the following abnormalities, if any of
the following laboratory abnormalities are present, the patient should be excluded:

- WBC < 3000/uL;

- Absolute neutrophil count < 1500/uL;

- Platelets < 100,000/uL;

- Total bilirubin > 1.5 x upper limit of normal;

- ALT or AST > 3 x upper limit of normal if no liver metastases or >5 upper limit
of normal in the presence of liver metastases;

- Concurrent or recent (within 1 month) use of thrombolytic agents, or full-dose
anticoagulants (except to maintain patency of preexisting, permanent indwelling IV
catheters) Of note, therapy with low-molecular weight heparin is acceptable as long
as the INR<2.0.

- Uncontrolled hypertension

- Grade II-IV peripheral vascular disease within the past year

- Prior allergic reactions to compounds of similar chemical or biologic composition to
TPI 287, paclitaxel or taxotere, Cremophor-EL-P, or other study agents

- Significant traumatic injury within the past 4 weeks

- Ongoing or active infection requiring parenteral antibiotics or with a fever >38.1°C
within 3 days of the first scheduled day of dosing

- Other concurrent uncontrolled illness which may interfere with the ability of the
patient to participate in the trial

We are a Cancer Social Network, Resource Directory & Education Hub supporting all those affected by cancer. knowcancer.com is intended to be solely for informational purposes and should not be a substitute for professional medical advice, diagnosis or treatment.